Cargando…
Predicting Response to Immunotherapy in Metastatic Renal Cell Carcinoma
SIMPLE SUMMARY: Immunotherapy-based treatment options have become standard of care in metastatic renal cell carcinoma. Despite significant improvement in overall survival with these therapies, the tumors of many patients will eventually progress. This review highlights the ongoing efforts to develop...
Autores principales: | Tucker, Matthew D., Rini, Brian I. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7565517/ https://www.ncbi.nlm.nih.gov/pubmed/32961934 http://dx.doi.org/10.3390/cancers12092662 |
Ejemplares similares
-
Complete Pathologic Responses With Immunotherapy in Metastatic Renal Cell Carcinoma: Case Reports
por: Tucker, Matthew D., et al.
Publicado: (2020) -
Axitinib in Metastatic Renal Cell Carcinoma
por: Mittal, Kriti, et al.
Publicado: (2012) -
Treatment of Refractory Metastatic Renal Cell Carcinoma
por: Vento, Joseph A., et al.
Publicado: (2022) -
The Role of Targeted Therapy in Metastatic Renal Cell Carcinoma
por: Unnithan, Jaya, et al.
Publicado: (2007) -
Novel immunotherapy in metastatic renal cell carcinoma
por: Cho, Yang Hyun, et al.
Publicado: (2017)